Amal Arahmani

3.6k total citations · 1 hit paper
21 papers, 1.1k citations indexed

About

Amal Arahmani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Amal Arahmani has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Amal Arahmani's work include HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (8 papers) and Breast Cancer Treatment Studies (7 papers). Amal Arahmani is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Advanced Breast Cancer Therapies (8 papers) and Breast Cancer Treatment Studies (7 papers). Amal Arahmani collaborates with scholars based in Belgium, Italy and United States. Amal Arahmani's co-authors include Giuseppe Viale, Martine Piccart, Evandro de Azambuja, Richard D. Gelber, Dimitrios Zardavas, Marion Procter, José Bines, Christelle Lévy, Mark Benyunes and Gϋnter von Minckwitz and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Amal Arahmani

20 papers receiving 1.0k citations

Hit Papers

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positiv... 2017 2026 2020 2023 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    2017 918 citations Gϋnter von Minckwitz, Marion Procter et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amal Arahmani Belgium 8 836 430 301 295 151 21 1.1k
Monika Patre Switzerland 14 1.0k 1.2× 176 0.4× 500 1.7× 324 1.1× 140 0.9× 24 1.2k
Frédérique Berger France 19 517 0.6× 411 1.0× 105 0.3× 323 1.1× 420 2.8× 64 1.0k
Cynthia R. Osborne United States 12 629 0.8× 291 0.7× 81 0.3× 270 0.9× 293 1.9× 30 882
Cédric Révil Switzerland 8 577 0.7× 234 0.5× 220 0.7× 307 1.0× 122 0.8× 23 807
Merdol Ibrahim United Kingdom 15 469 0.6× 275 0.6× 262 0.9× 146 0.5× 254 1.7× 19 735
Oliver Stoß Germany 10 532 0.6× 138 0.3× 254 0.8× 334 1.1× 471 3.1× 16 1.0k
Ivonne Villalobos United States 10 681 0.8× 309 0.7× 398 1.3× 148 0.5× 296 2.0× 13 863
Erica Stringer-Reasor United States 16 388 0.5× 268 0.6× 72 0.2× 231 0.8× 282 1.9× 48 738
Sara Ravaioli Italy 16 351 0.4× 330 0.8× 212 0.7× 439 1.5× 258 1.7× 54 939
Amelia Zelnak United States 15 530 0.6× 310 0.7× 54 0.2× 388 1.3× 318 2.1× 45 1.0k

Countries citing papers authored by Amal Arahmani

Since Specialization
Citations

This map shows the geographic impact of Amal Arahmani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amal Arahmani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amal Arahmani more than expected).

Fields of papers citing papers by Amal Arahmani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amal Arahmani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amal Arahmani. The network helps show where Amal Arahmani may publish in the future.

Co-authorship network of co-authors of Amal Arahmani

This figure shows the co-authorship network connecting the top 25 collaborators of Amal Arahmani. A scholar is included among the top collaborators of Amal Arahmani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amal Arahmani. Amal Arahmani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Reilly, Séamus, Inês Vaz-Luís, Virginie Adam, et al.. (2025). Advancing equitable access to innovation in breast cancer. npj Breast Cancer. 11(1). 71–71. 1 indexed citations
2.
Debien, Véronique, Virginie Adam, Elisa Agostinetto, et al.. (2023). DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer. Future Oncology. 19(24). 1655–1667. 3 indexed citations
3.
4.
5.
Debien, Véronique, Virginie Adam, Rafael Caparica, et al.. (2022). DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade.. Journal of Clinical Oncology. 40(16_suppl). TPS621–TPS621. 8 indexed citations
6.
7.
8.
Bines, José, Emma Clark, Claire Barton, et al.. (2021). Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. British Journal of Cancer. 125(1). 38–47. 5 indexed citations
9.
Bines, José, Marion Procter, Eleonora Restuccia, et al.. (2019). Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clinical Breast Cancer. 20(2). 174–181.e3. 4 indexed citations
10.
Gray, Kathryn P., Meinir Krishnasamy, Meredith M. Regan, et al.. (2019). Abstract OT2-04-03: Examining personalized radiation therapy (EXPERT): A randomised phase III trial of adjuvant radiotherapy vs observation in patients with molecularly characterized luminal A breast cancer. Cancer Research. 79(4_Supplement). OT2–4. 4 indexed citations
11.
Hui, Rina, Andrew D.J. Pearson, Christine Campbell, et al.. (2018). Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. Annals of Oncology. 29. viii93–viii93. 2 indexed citations
12.
Bines, José, Evandro de Azambuja, Marion Procter, et al.. (2018). Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer. Cancer Research. 78(4_Supplement). P1–13. 1 indexed citations
13.
14.
Minckwitz, Gϋnter von, Marion Procter, Evandro de Azambuja, et al.. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. New England Journal of Medicine. 377(2). 122–131. 918 indexed citations breakdown →
15.
Tutt, Andrew, Bella Kaufman, Judy E. Garber, et al.. (2017). OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). Annals of Oncology. 28. v67–v67. 16 indexed citations
16.
17.
18.
Tutt, Andrew, Bella Kaufman, Richard D. Gelber, et al.. (2015). OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).. Journal of Clinical Oncology. 33(15_suppl). TPS1109–TPS1109. 16 indexed citations
19.
Pugliano, Lina, Debora Fumagalli, Alexandre Irrthum, et al.. (2011). Integrate: a new model in collaborative breast cancer research. The Breast. 20. S26–S27. 1 indexed citations
20.
Burlet, Arlette, et al.. (1990). Neuronal Uptake of Monoclonal Anti‐Vasopressin Antibodies in vivo and Relationship with the Physiological Status of Vasopressin Neurosecretory Cells. Journal of Neuroendocrinology. 2(3). 355–361. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monika Patre Breakdown of academic impact, for papers by Frédérique Berger Breakdown of academic impact, for papers by Cynthia R. Osborne Breakdown of academic impact, for papers by Cédric Révil Breakdown of academic impact, for papers by Merdol Ibrahim Breakdown of academic impact, for papers by Oliver Stoß Breakdown of academic impact, for papers by Ivonne Villalobos Breakdown of academic impact, for papers by Erica Stringer-Reasor Breakdown of academic impact, for papers by Sara Ravaioli Breakdown of academic impact, for papers by Amelia Zelnak
Rankless by CCL
2026